Keyphrases
Solid Tumors
100%
Cell Therapy
100%
Gene Editing
100%
T Cells
100%
Recombinant
100%
Gene Augmentation Therapy
100%
T Cell Receptor-engineered T Cells
80%
Solid Tumor Therapy
60%
Genome Editing
40%
Potential Treatments
40%
Infiltration Rate
40%
Tumor
20%
Clinical Trials
20%
Recent Advances
20%
Hematological Malignancies
20%
Gene-gene
20%
Treatment Options
20%
Immune Cells
20%
Tumor Heterogeneity
20%
Chimeric Antigen Receptor T Cells (CAR-T)
20%
Tumor Antigen
20%
Cancer Patients
20%
Adoptive Cell Therapy
20%
Chemokines
20%
Severe Adverse Events
20%
T-cell Reactivity
20%
Gene Therapy
20%
Tumor Stroma
20%
Potential Risk
20%
Ongoing Clinical Trials
20%
Efficient Delivery
20%
Immunosuppressive Microenvironment
20%
Inhibitory Pathways
20%
Therapeutic Treatment
20%
Off-target Toxicity
20%
Gene Engineering
20%
Safety Switch
20%
Engineering Technology
20%
TCR Transgenes
20%
TCR Expression
20%
Medicine and Dentistry
Solid Malignant Neoplasm
100%
T Cell
100%
Cell Therapy
100%
T Lymphocyte Receptor
57%
Neoplasm
28%
Clinical Trial
28%
Stroma
28%
T Cell Receptor
28%
Malignant Neoplasm
14%
Adverse Event
14%
Immunocompetent Cell
14%
Transgene
14%
Tumor Antigen
14%
Cytokine
14%
Receptor
14%
Chimeric Antigen Receptor T-Cell
14%
Hematologic Malignancy
14%
Chemokine
14%
Tumour Heterogeneity
14%
Gene Therapy
14%
Immunosuppressive Drug
14%
Recombinant
14%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
T Lymphocyte Receptor
80%
Neoplasm
60%
Clinical Trial
40%
Malignant Neoplasm
20%
Receptor
20%
Chimeric Antigen Receptor
20%
Cytokine
20%
Hematologic Malignancy
20%
Chemokine
20%
Adverse Event
20%
Immunosuppressive Agent
20%
Tumor Antigen
20%
Recombinant
20%